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Introduction: The receptor for advanced glycation end products (RAGE) is a transmembrane receptor of the
immunoglobulin superfamily, it plays pivotal roles in the pathogenesis of sepsis in several ways. Our previous study
showed that rs1800625 (−429T/C) revealed a strong clinical relevance with sepsis morbidity rate and multiple organ
dysfunction syndrome (MODS) in patients with major trauma. In this study, we enlarged the sample size, added
two validation populations and examined the expression of RAGE on the surface of peripheral leukocytes to ex vivo
lipopolysaccharide (LPS) stimulation in subjects with different genotypes.
Methods: Rs1800625 was genotyped using pyrosequencing in 837 Chinese Han patients with major trauma in
Chongqing. We then validated the clinical relevance in 340 Zhejiang and 347 Yunnan patients. The expression of
RAGE on the surface of peripheral blood mononuclear cells was measured by flow cytometric analysis.
Results: The results indicated that rs1800625 was significantly associated with sepsis morbidity rate and MODS in
patients with major trauma in the Chongqing, Zhejiang and Yunnan districts. Patients with CC genotype had lower
sepsis morbidity rate and MODS after major trauma. Furthermore, patients with CC genotype had significantly
higher RAGE expression (P = 0.009).
Conclusions: The rs1800625 polymorphism is a functional single nucleotide polymorphism and confers host
susceptibility to sepsis and MODS in patients with major trauma.Introduction
The traditional view of trauma as ‘accidents’, or random
events, has resulted in the historical neglect of this area
of public health. The most recent estimates show that
trauma is among the leading causes of death and disabil-
ity in the world. In 1998, about 5.8 million people (97.9
per 100,000 population) died of trauma worldwide, and
trauma caused 16% of the global burden of disease [1].
Trauma affects mostly young people, often causing death
or long-term disability. With great improvements in the
emergency care system, the majority of severe trauma* Correspondence: hellojjx@126.com
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unless otherwise stated.patients survived traumatic injury. However, many still
suffer from complications after admission, leading to in-
hospital death. Sepsis and multiple organ dysfunction syn-
drome (MODS) are common and severe complications in
trauma patients [2]. Therefore, preventing sepsis and
MODS is critical to the treatment of patients who survive
major trauma. Because of this, establishing an early diag-
nosis of sepsis and MODS is an essential prerequisite.
The receptor for advanced glycation end products
(RAGE) is a transmembrane receptor of the immuno-
globulin superfamily; it has been recognized as a multi-
ligand receptor. RAGE plays pivotal roles in innate
immune responses as a pattern-recognition receptor
(PRR) in sensing both ‘pathogen-associated molecular
patterns’ (PAMPs) and endogenous damage-associatedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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found to be recognized by RAGE include advanced gly-
cation end products (AGEs), amyloid β-peptide, DNA-
binding protein high-mobility group box-1 (HMGBl)
and S100/calgranulins [3-7]. RAGE has been suggested
to be involved in the pathogenesis of sepsis in several
ways. The cellular effects resulting from the activation of
RAGE by the above-mentioned ligands are mediated by
multiple intracellular signaling pathways, including nu-
clear factor-κB (NF-κB), leading to the transcription of
proinflammatory factors [8]. RAGE deficiency improved
survival in a model of abdominal polymicrobial sepsis
induced by cecal ligation and puncture (CLP) [9].
Our previous study shows that rs1800625 reveals a
strong clinical relevance, showing lower sepsis morbidity
rates and MODS scores in patients with the variant C
allele [10]. Using a reporter gene assay system, we investi-
gated the effect of rs1800625 on RAGE promoter activity.
The results suggested that T to C variation at position −429
could significantly reduce the transcriptional activity of
RAGE promoter. Our further study showed that rs1800625
was significantly associated with lower responsiveness of
peripheral blood leukocytes in response to lipopolysacchar-
ide (LPS) stimulation, showing much lower levels of tumor
necrosis factor alpha (TNFα) in patients carrying the C
allele. Thus, we enlarged the sample size and added two
validation populations to further investigate the clinical
relevance of -429 T/C with the development of sepsis and
MODS in patients with major trauma. Furthermore, to
examine whether there is a functional linkage between
rs1800625 and membrane-bound RAGE protein expres-
sion, we examined the expression of RAGE on the surface
of peripheral leukocytes to ex vivo LPS stimulation in sub-
jects with different genotypes.
Materials and methods
Study populations and clinical evaluation
Three independent patient cohorts were recruited for
this study, Chongqing (n = 837), Zhejiang (n = 340) and
Yunnan (n = 367). They were admitted to the Depart-
ment of Trauma Surgery in the Daping Hospital and the
Chongqing Emergency Medical Center between 1 January
2005 and 1 October 2013, and to the Department of
Trauma and Emergency in the Second Affiliated Hospital,
Zhejiang University between 1 January 2008 and 1 October
2013 and the Department of Trauma and Emergency in
the General Hospital of Kunming between 1 January 2007
and 1 October 2013 in Yunnan province. They were en-
rolled in the study if they met the following inclusion cri-
teria: (1) between 18 and 65 years of age, (2) expected
Injury Severity Score (ISS) greater than 16 combined with
the presence of at least one life-threatening injury and at
least one additional severe injury in another part of the
body. Patients were not eligible if they had penetratinginjuries or preexisting cardiovascular, respiratory, renal,
hepatic, hematologic or immunologic diseases. ISSs were
determined by independent evaluators in accordance with
the abbreviated injury scale developed in 2005 [11]. All pa-
tients requiring surgical intervention received standard
surgical care and postoperative intensive care unit (ICU)
treatment. The patients from Chongqing district consti-
tuted the inception cohort, which was used to screen the
single nucleotide polymorphisms (SNPs) with possible
clinical relevance. The patients from Yunnan and Zhejiang
districts constituted the validation cohorts. The protocol
was approved by the Ethical and Protocol Review Com-
mittee of the Third Military Medical University, and in-
formed consent was obtained from the patients and the
patients’ next of kin. Patient confidentiality was preserved
according to the guidelines for studies of human subjects.
The diagnosis of sepsis met the criteria recommended
by the American College of Chest Physicians and Society
of Critical Care Medicine Consensus Conference [12].
Infection was defined as a clinically obvious source or
positive bacterial cultures. Pneumonia was diagnosed
when a predominant organism was isolated from appro-
priately obtained sputum cultures in the setting of puru-
lent sputum production and/or a new or changing
pulmonary infiltrate on patients’ chest X-ray film. Blood-
stream infections were diagnosed based on isolation of a
predominant organism from blood cultures obtained
under sterile conditions. Criteria for urinary tract infec-
tions included the presence of clinical symptoms and >10
white blood cells/high-power field on microscopic exam-
ination or isolation of >105 organisms/ml of urine or >104
organisms. Criteria for catheter-related infections included
isolation of >15 colony-forming units from catheter tips
cultured only when infection was suspected. Wound infec-
tion was identified by drainage of purulent material from
the wound. Daily physiologic and laboratory data were
collected during the hospital stay and clinical events were
recorded thereafter until death or discharge from the hos-
pital [13,14]. Multiple organ dysfunction scores were
calculated as the sum of the simultaneously obtained indi-
vidual organ scores on each hospital day [15]. MODS
scores and the presence of sepsis were determined by indi-
viduals who did not know the patients’ genotypes.
Genotyping
Genomic DNA was isolated from whole blood using
Wizard genomic DNA purification kit (Promega, Madison,
WI, USA). Pyrosequencing was used for genotyping of
rs1800625 according to our previous reports [13,14]. The
PCR primers and the annealing temperature were shown
in Table 1. Genotyping was performed in a blinded fash-
ion without knowledge of the patients’ clinical data, and
10% of the samples were further confirmed by direct
sequencing.
Table 1 Primers and PCR conditions
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The expression of RAGE on the surface of peripheral
blood mononuclear cells was measured by flow cytometric
analysis. The whole blood samples collected from 42
healthy volunteers were mixed at a dilution ratio of 1:1
(vol/vol) using RPMI 1640 culture medium, and incubated
with 100 ng/ml of Escherichia coli LPS (O26:B6) at a
temperature of 37°C for 4 hours. LPS-activated peripheral
blood mononuclear cell samples at a density of 1 × 106
cells/ml were stained with anti-human RAGE monoclonal
antibody (Abcam, Cambridge, UK). Then cells were stained
with fluorescein isothiocyanate (FITC)-conjugated donkey
anti-mouse immunoglobulin G (IgG) (Life Technology,
Carlsbad, CA, USA). After washing, the proportion of
RAGE-positive cells was determined using flow cytometer.
The RAGE expression on monocytes was presented as
mean fluorescence intensity (MFI).
Statistical analysis
Sample size was calculated using online Power and Sam-
ple Size Program software [16]. The desired power of our
study was set at 80% with a significance level of 0.05 in a
two-sided test. We chose the log-additive inheritance
model, which is the most suitable for polygenic diseases.
Allele frequency was determined by gene counting.
Genotype distribution was tested for departure from the
Hardy-Weinberg equilibrium (HWE) using χ2 analyses.
The extent of pairwise linkage disequilibrium between
polymorphisms was determined by the Haploview (ver-
sion 4.0) software. The association between polymor-
phisms and MOD scores was performed using analysis
of one-way analysis of variance (ANOVA) testing with
age, sex ratio, and injury severity to adjust for possible
confounding effects. Three genetic models (dominant,
recessive and allele-dose effects) were used. The associ-
ation of genotypes with sepsis morbidity rate was deter-
mined by χ2 analysis. Odds ratios with 95% confidence
intervals were calculated by multiple logistic regression
analyses to estimate the relative risk of sepsis. Age, sex
ratio, and injury severity were used as covariances of
multiple logistic regression. All statistical analysis was
carried out using SPSS version 13.0 (SPSS Inc, Chicago,
IL, USA) [13,14].
Results
Study population and clinical evaluation
Three independent patient cohorts were recruited for
this study, Chongqing (n = 837), Zhejiang (n = 340) andYunnan (n = 367). All patients survived at least 48 hours
after admission. Baseline data of the patients are shown
in Table 2. Patients were mostly young in age (mean age
41.1 ± 13.4, 42.5 ± 12.0 and 37.6 ± 12.5), and had sus-
tained severe injuries (mean ISS 22.3 ± 9.4, 21.7 ± 7.7,
and 21.3 ± 9.2). Sepsis morbidity rate was 41.3%, 37.9%
and 35.4% in Chongqing, Zhejiang and Yunnan cohorts.
Organ dysfunction occurred in 51.4%, 56.2%, and 57.5%
of patients in the Chongqing, Yunnan, and Zhejiang co-
horts, respectively, among which 162 (19.4%), 79 (23.2%),
and 86 (23.4%) patients exhibited dysfunction in two or
more organs. Median time point for sepsis occurrence in
the whole study cohort was 6 days (interquartile range 5.0
to 8.5 days). Median time point for organ dysfunction oc-
currence in the whole study cohort was 7 days (interquar-
tile range 5.0 to 8.5 days).
Clinical relevance of rs1800625 in trauma patients from
Chongqing district
First, 837 Chinese Han patients with major trauma from
Chongqing district were used to investigate the clinical
relevance of rs1800625. The minor allele frequency (MAF)
of rs1800625 was 14.2% in Chongqing districts (Table 3).
The genotype distribution was in agreement with the
HWE (P >0.05, Table 3).
As shown in Table 4, there were no significant differ-
ences in age, gender ratio and ISS among patients strati-
fied according to the different genotypes of rs1800625.
The patients carrying T allele of rs1800625 revealed sig-
nificantly increased risk of sepsis and higher MODS
scores when compared to those carrying C allele (P =
0.002 for sepsis morbidity rate and P = 0.001 for MODS
scores in case of dominant effect, P = 0.032 for MODS
scores in case of recessive effect). Data from regression
analyses further indicated that the association of this
polymorphism was in significant allele-dose effect with
sepsis morbidity rate (odds ratio (OR) = 0.378, 95% con-
fidence interval (CI): 0.254 to 0.893, P = 0.017).
Validation of the clinical relevance of rs1800625 in
Zhejiang and Yunnan trauma patients
We further validate the results in two additional distinct
cohorts (Zhejiang and Yunnan populations). Zhejiang
(N = 340) and Yunnan (N = 347) provinces are located in
eastern and southern China. The characteristics of trauma
patients in these two validation cohorts are presented in
Table 1. The overall MAF of rs1800625 in Zhejiang and
Yunnan populations are similar to those in Chongqing.
Table 2 Overall clinical characteristics of patients with major trauma
Screening cohort Validation cohorts
Chongqing (N = 837) Zhejiang (N = 340) Yunnan (N = 367)
Age (yrs) 41.1 ± 13.4 (18-65) 42.5 ± 12.0 (19-65) 37.6 ± 12.5 (18-65)
Male/female, n 672/165 266/74 282/85
Injured body regions, n (%)
Head, n 458 (54.7) 248 (72.9) 225 (61.3)
Thorax, n 513 (61.2) 209 (61.5) 186 (50.7)
Abdomen, n 389 (46.4) 118 (34.7) 105 (28.6)
Extremities, n 425 (50.8) 179 (52.6) 196 (53.4)
Number of regions injured, n (%)
One, n 435 (52.0) 146 (42.9) 157 (42.8)
Two, n 267 (31.9) 129 (37.9) 131 (35.7)
Three or above, n 135 (16.1) 65 (19.1) 79 (21.5)
ISS 22.3 ± 9.4 21.7 ± 7.7 21.3 ± 9.2
≥16, <25, n (%) 510 (60.9) 197 (57.9) 228 (62.1)
≥25, n (%) 327 (39.1) 143 (42.1) 139 (37.9)
Organ dysfunction, n (%)
One, n 268 (32.2) 112 (32.9) 125 (34.1)
Two, n 121 (14.5) 56 (16.5) 51 (13.9)
Three or above, n 41 (4.9) 23 (6.8) 35 (9.5)
Sepsis, n (%) 346 (41.3) 129 (37.9) 130 (35.4)
Source of infection, %
Respiratory tract infection 41.6 39.7 43.2
Primary bloodstream infection 21.5 24.1 19.9
Urinary tract infection 16.2 11.2 12.1
Catheter-associated infection 10.9 9.1 9.3
Wound infection 7.4 9.1 10.1
Others* 2.4 6.8 5.4
Pathogens, % (positive blood cultures)
Gram-negative 22.3 25.7 29.5
Gram-positive 17.6 13.2 12.8
Fungi 2.8 3.5 3.6
Mixed Gram-negative and -positive 5.9 7.5 8.5
Negative blood cultures 54.0 55.0 57.0
ISS, Injury Severity Score.




Patients Databank Wild Heterozygous Variant
Chongqing 837 14.2
12.2
620 195 22 0.16
Zhejiang 340 10.7 271 65 4 0.96
Yunnan 367 14.9 269 86 12 0.12
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Table 4 Clinical relevance of rs1800625 among trauma patients in the three cohorts
Genotypes N Age (yr) Sex (M/F) ISS Sepsis, n/% MODS score
Chongqing
TT 620 40.8 ± 13.1 494/126 22.6 ± 9.3 275 (46.8%) 6.9 ± 2.2
TC 195 41.9 ± 14.5 157/38 21.5 ± 9.7 65 (33.3%) 6.0 ± 2.0
CC 22 41.0 ± 11.4 21/1 20.0 ± 9.4 6 (27.3%) 5.2 ± 1.7
a1 a2, b1
Zhejiang
TT 271 42.3 ± 12.7 212/59 21.7 ± 7.7 113 (41.7%) 7.5 ± 2.5
TC 65 42.8 ± 16.2 50/15 21.9 ± 7.6 15 (23.1%) 6.8 ± 2.6
CC 4 45.8 ± 19.8 4/0 18.8 ± 6.5 1 (25.0%) 5.9 ± 3.1
a3 a4
Yunnan
TT 269 37.4 ± 12.5 208/61 21.3 ± 9.0 103 (38.3%) 7.2 ± 2.0
TC 86 38.7 ± 12.0 64/22 20.8 ± 9.8 24 (27.9%) 6.3 ± 2.1
CC 12 33.8 ± 14.4 10/2 24.8 ± 8.7 3 (25.0%) 5.8 ± 2.6
a5 a6
a: dominant effect (variant homozygotes + heterozygotes vs. wild homozygotes) as analyzed by ANCOVA, a1P = 0.002, a2P = 0.001, a3P = 0.003, a4P = 0.032, a5P = 0.047,
a3P = 0.016, a4P = 0.042, a5P = 0.012, a6P = 0.026; b: recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes) as analyzed by ANCOVA, b1P = 0.032. ISS.
Injury Severity Score; MODS, multiple organ dysfunction syndrome.
Figure 1 Association of the rs1800625 with LPS-induced
expression of RAGE protein. The whole blood samples were
collected from 42 healthy volunteers (TT: N = 32, TC: N = 8, CC: N = 2).
The RAGE expression on the peripheral leukocytes was assayed using
flow cytometry and was presented as MFI. One-way ANOVA was used
to assess statistical significance. P= 0.009 for dominant association (CC +
TC vs. TT). ANOVA, analysis of variance; LPS lipopolysaccharide; RAGE,
the receptor for advanced glycation end products.
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As shown in Table 4, rs1800625 was also shown to be
strongly associated with risk of the development of post-
traumatic sepsis in both independent validation cohorts.
The patients carrying the variant T allele had significantly
higher sepsis morbidity rate than those carrying the wild C
allele (P= 0.016 for sepsis morbidity rate and P= 0.042 for
MODS scores in case of dominant effect in Yunnan cohorts.
P = 0.016 for sepsis morbidity rate and P= 0.042 for MODS
scores in case of dominant effect in Zhejiang cohorts.
P = 0.012 for sepsis morbidity rate and P = 0.026 for MODS
scores in case of dominant effect in Yunnan cohorts).
Association of rs1800625 with RAGE protein expression
To examine whether there is a functional linkage be-
tween rs1800625 and membrane-bound RAGE protein
expression, we examined the expression of RAGE on the
surface of peripheral leukocytes to ex vivo LPS stimulation
in subjects with different genotypes. The RAGE expres-
sion was shown to be well associated with rs1800625 poly-
morphism, showing a significant difference in case of
dominant effects (P = 0.009) (genotype MFI: CC, 28.5 ±
5.3; TC, 25.3 ± 5.6; CC, 21.4 ± 4.7; Figure 1).
Discussion
Sepsis was defined as a systemic inflammatory response
to infection. Sepsis and MODS were the most common
causes of mortality for septic patients in the ICU [17].
Evidence from both family-based research and genetic
association studies demonstrated that a significant portion
of the variability in susceptibility to outcome of sepsis was
due to genetic factors [18]. Delineating the variation in
genes and associated differences in immune inflammatory
response might contribute to the development of newgenetically tailored diagnostic and therapeutic interven-
tions that will improve outcome in critically ill patients.
RAGE is expressed in many cell types involved in the
innate immune system and is able to recognize a wide
range of endogenous molecules that are released during
various conditions of inflammation and/or injury. Acti-
vation of RAGE results in sustained activation of NF-κB,
thereby converting transient proinflammatory responses
into lasting cellular dysfunction [19]. A number of publi-
cations have revealed roles for the -429T/C as a marker
for the diabetic/prediabetic state [20], cardiovascular mor-
tality [21] and colorectal cancer [22]. In diabetic subjects,
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and occurred with an increased incidence in type 1 dia-
betic patients [20]. −429 C carriers have an increased risk
for colorectal cancer. However, some studies have not re-
vealed many disease associations of -429T/C with type 2
diabetic retinopathy, cardiovascular disease, or incident
myocardial infarction [23-25]. Our previous study showed
that rs1800625 C allele carriers had lower sepsis morbidity
rate and MODS scores [10]. Results from reporter gene
assay system suggested that T to C variation of rs1800625
could significantly reduce the transcriptional activity of
RAGE promoter. Thus, we enlarged the sample size and
added two validation populations to further investigate the
clinical relevance of rs1800625 with the development of
sepsis and MODS in patients with major trauma.
In both study populations, the −429TT genotype was
overrepresented in major trauma patients with sepsis
and those with higher MODS scores, suggesting a sus-
ceptible role of the TT genotype to the onset of sepsis
and MODS. In our study, we further investigated the as-
sociation of rs1800625 with RAGE protein expression.
Consistently, we found that RAGE expression was shown
to be well associated with rs1800625 polymorphism,
−429TT carriers have higher RGAE protein level. Thus,
the rs1800625 polymorphism might be a causal risk allele
for sepsis and MODS in patients with major trauma, so it
might be used as a biomarker.
However, there are several limitations in our study. First,
our study was restricted to Han Chinese and whether the
findings can be generalized to other ethnic groups needs
further evaluation. Second, the sample size of patients we
recruited, though being adequate for the Chongqing co-
hort, was not enough for the Yunnan and Zhejiang co-
horts. The values of power for rs1800625 are shown to be
0.68 and 0.71, respectively, at a significance of 0.05. Add-
itional large studies are needed for the validation cohorts.
Conclusions
The present study enlarged the sample size and added two
validation populations to further investigate the clinical
relevance of rs1800625 with the development of sepsis
and MODS in patients with major trauma. The −429TT
genotype was overrepresented in major trauma patients
with sepsis and those with higher MODS scores both in
Chongqing and two validation cohorts, suggesting a sus-
ceptible role of the TT genotype to the onset of sepsis and
MODS. In addition, RAGE expression was shown to be
well associated with rs1800625 polymorphism, −429TT
carriers have higher RGAE protein level.
Key messages
 Rs1800625 reveals a strong clinical relevance,
showing lower sepsis morbidity rate and MODSscores in the patients with the variant C allele both
in the Chongqing, Yunnan and Zhejiang cohorts.
 RAGE expression was also shown to be well
associated with rs1800625 polymorphism, −429CC
carriers have lower RGAE protein level.
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